A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission Academic Article uri icon

Overview

MeSH Major

  • Anilides
  • Antineoplastic Agents
  • Maintenance Chemotherapy
  • Ovarian Neoplasms
  • Pyridines

abstract

  • In this study, the sought magnitude of increase in PFS was not achieved for vismodegib maintenance versus placebo in patients with ovarian cancer in second or third CR. The frequency of Hedgehog ligand expression was lower than expected.

publication date

  • December 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-12-1796

PubMed ID

  • 23032746

Additional Document Info

start page

  • 6509

end page

  • 18

volume

  • 18

number

  • 23